510 related articles for article (PubMed ID: 28621564)
1. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
Currow DC; Skipworth RJ
Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
[TBL] [Abstract][Full Text] [Related]
2. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Graf SA; Garcia JM
Drug Des Devel Ther; 2017; 11():2325-2331. PubMed ID: 28848326
[TBL] [Abstract][Full Text] [Related]
3. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
4. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
6. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Bai Y; Hu Y; Zhao Y; Yu X; Xu J; Hua Z; Zhao Z
Support Care Cancer; 2017 May; 25(5):1651-1659. PubMed ID: 28074289
[TBL] [Abstract][Full Text] [Related]
7. Anamorelin for cancer cachexia.
Nishie K; Sato S; Hanaoka M
Drugs Today (Barc); 2022 Mar; 58(3):97-104. PubMed ID: 35274629
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Naito T; Uchino J; Kojima T; Matano Y; Minato K; Tanaka K; Mizukami T; Atagi S; Higashiguchi T; Muro K; Takayama K; Furuse J; Morishima E; Takiguchi T; Tamura K
Cancer; 2022 May; 128(10):2025-2035. PubMed ID: 35195274
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.
Currow DC; Maddocks M; Cella D; Muscaritoli M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400622
[TBL] [Abstract][Full Text] [Related]
10. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Fonseca GWPD; von Haehling S
Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
[TBL] [Abstract][Full Text] [Related]
11. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.
Currow DC; Abernethy AP
Future Oncol; 2014 Apr; 10(5):789-802. PubMed ID: 24472001
[TBL] [Abstract][Full Text] [Related]
12. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.
Hamauchi S; Furuse J; Takano T; Munemoto Y; Furuya K; Baba H; Takeuchi M; Choda Y; Higashiguchi T; Naito T; Muro K; Takayama K; Oyama S; Takiguchi T; Komura N; Tamura K
Cancer; 2019 Dec; 125(23):4294-4302. PubMed ID: 31415709
[TBL] [Abstract][Full Text] [Related]
14. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
[TBL] [Abstract][Full Text] [Related]
15. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
Advani SM; Advani PG; VonVille HM; Jafri SH
BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
[TBL] [Abstract][Full Text] [Related]
17. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
[TBL] [Abstract][Full Text] [Related]
18. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
[TBL] [Abstract][Full Text] [Related]
19. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Malik JS; Yennurajalingam S
Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
[TBL] [Abstract][Full Text] [Related]
20. What is next after anamorelin?
Garcia JM
Curr Opin Support Palliat Care; 2017 Dec; 11(4):266-271. PubMed ID: 28957883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
